Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: A large multicenter AGEO study

Journal of the National Cancer Institute

Volumn 108, Issue 7, 2016, Pages

  Tougeron, David ^a,b   Mouillet, Guillaume ^c   Trouilloud, Isabelle ^d   Lecomte, Thierry ^e,f   Coriat, Romain ^g   Aparicio, Thomas ^h   Des Guetz, Gaetan ^h   Lecaille, Cedric ⁱ   Artru, Pascal ^j   Sickersen, Gaelle ^a   Cauchin, Estelle ^k   Sefrioui, David ^l   Boussaha, Tarek ^m   Ferru, Aurelie ^a   Matysiak Budnik, Tamara ^k   Silvain, Christine ^a,b   Karayan Tapon, Lucie ^a   Pages, Jean Christophe ^f   Vernerey, Dewi ^e   Bonnetain, Franck ^e   Michel, Pierre ^l   Taieb, Julien ^g,n   Zaanan, Aziz ^g,n   more..

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

^e Department of Gastroenterology ^*

^f UNIVERSITÉ DE TOURS   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h AVICENNE HOSPITAL   (France)

ⁱ Clinique Bordeaux Nord   (France)

^j Private Hospital Jean Mermoz   (France)

^k NANTES UNIVERSITY HOSPITAL   (France)

^l ROUEN UNIVERSITY HOSPITAL   (France)

^m HÔPITAL SAINT ANTOINE   (France)

ⁿ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROPYRIMIDINE; OXALIPLATIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; PYRIMIDINE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PERINEURAL INVASION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR PERFORATION; ADJUVANT CHEMOTHERAPY; BRAIN TUMOR; CLINICAL TRIAL; COLONIC NEOPLASMS; COLORECTAL TUMOR; FAMILIAL CANCER; GENETICS; GERMLINE MUTATION; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; GERM-LINE MUTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC SYNDROMES, HEREDITARY; ORGANOPLATINUM COMPOUNDS; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84979255808     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv438     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338(21):1481-1487.
3. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998;95(12):6870-6875.
4. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96(15):8681-8686.
5. Domingo E, Niessen RC, Oliveira C, et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene. 2005;24(24):3995-3998.
6. Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet. 2004;41(9):664-668.
7. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247-257.
8. Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev. 2001;10(9):917-923.
9. Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-Fluorouracilbased adjuvant therapy. J Natl Cancer Inst. 2011;103(11):863-875.
10. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609-618.
11. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6):352-358.
12. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219-3226.
13. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109-3116.
14. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198-2204.
15. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465-1471.
16. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996;56(21):4881-4886.
17. Tournigand C, Andre T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol. 2012;30(27):3353-3360.
18. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. New Engl J Med. 2005;353(25):2654-2666.
19. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248-5257.
20. Suraweera N, Duval A, Reperant M, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology. 2002;123(6):1804-1811.
21. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch Syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999;116(6):1453-1456.
22. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch Syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261-268.
23. Zaanan A, Cuilliere-Dartigues P, Guilloux A, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 2010;21(4):772-780.
24. Zaanan A, Flejou JF, Emile JF, et al. Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy. Clin Cancer Res. 2011;17(23):7470-7478.
25. Des Guetz G, Schischmanoff O, Nicolas P, et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer. 2009;45(10):1890-1896.
26. Flou J, Andr'T, Chibaudel B, et al. Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study. J Clin Oncol. 2013;31(Suppl):Abstr 3524.
27. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-2351.
28. Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012;18(23):6531-6541.
29. Gavin PG, Paik S, Yothers G, Pogue-Geile KL. Colon cancer mutation: prognosis/ prediction-response. Clin Cancer Res. 2013;19(5):1301.
30. Zaanan A, Bonnetain F, Sinicrope FA, Laurent-Puig P, Taieb J. Colon cancer mutation: prognosis/prediction-letter. Clin Cancer Res. 2013;19(5):1300.
31. Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology. 1999;117(1):123-131.
32. Sargent D, Shi Q, Yothers G, et al. Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. J Clin Oncol. 2014;32(5s):Abstr 3507.
33. Tougeron D, Sickersen G, Mouillet G, et al. Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study. Eur J Cancer. 2015;51(8):925-934.
34. Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105(15):1151-1156.
35. Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012;18(3):890-900.
36. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res. 2003;9(8):2898-2903.
37. Chagpar R, Xing Y, Chiang YJ, et al. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol. 2012;30(9):972-979.
38. Kahn KL, Adams JL, Weeks JC, et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA. 2010;303:1037-1045.